BD (Becton, Dickinson and Company), a leading global medical technology company announced it is investing $100 million in its Holdrege, Neb. facility to expand capacity for its insulin syringe manufacturing operations.
The investment will be used for new technology and manufacturing equipment to expand capacity for BD insulin syringes. BD already produces more than 2 billion insulin syringes each year, which averages to be more than 250,000 syringes per hour.
About 40 percent of people with diabetes who inject insulin use syringes as part of their diabetes management regimen,” said Ken Miller, worldwide president of Diabetes Care for BD. This investment will provide benefits to this diabetes population and underscores our commitment to supply high-quality, industry-leading insulin syringes to patients.
|Company Name||BD (Becton, Dickinson and Company)|
|Estimated Cost||$100 Million|